Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy-Reference-Cited by-同舟云学术

Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy

Published:2017-07-31 Issue:9 Volume:26 Page:1061-1070
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Bucher Bartelson Becki¹,Le Lait M. Claire¹,Green Jody L.¹,Cepeda M. Soledad²,Coplan Paul M.³,Maziere Jean-Yves⁴,Wedin Gregory P.⁵,Dart Richard C.¹

Affiliation:

1. Rocky Mountain Poison and Drug Center; Denver Health and Hospital Authority; Denver CO USA

2. Janssen Research and Development; Titusville NJ USA

3. Purdue Pharma; Stamford CT USA

4. RPC Company; Columbus OH USA

5. Upsher-Smith Laboratories, LLC; Maple Grove MN USA

Funder

REMS Program Companies, a consortium of companies that sponsor the ER/LA opioid analgesic REMS

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference35 articles.

1. ER/LA Opioid Analgesics REMS Program Companies Selected important safety information: abuse potential and risk of life-threatening respiratory depression http://www.er-la-opioidrems.com/IwgUI/rems/pdf/important_safety_information.pdf

2. INCB Narcotic drugs report 2013: estimated world requirements for 2014-statistics for 2012 http://www.incb.org/incb/en/narcotic-drugs/Technical_Reports/2013/narcotic-drugs-technical-report-2013.html

3. Increases in drug and opioid overdose deaths-United States, 2000-2014;Rudd;Morbidity and Mortality Weekly Report (MMWR),2016

4. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011;Chen;National Center for Health Statistics Data Brief 2014; no 166

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benzodiazepines: Thinking outside the black box;Journal of Clinical Pharmacy and Therapeutics;2020-12-21

2. Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review;Drug Safety;2020-02-04

3. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration;JAMA Internal Medicine;2020-02-01

4. Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients;Postgraduate Medicine;2019-11-13

5. Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy;Pain Medicine;2019-03-16